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͞The familial co-aggregation of ADHD and intellectual disability: a register-based family study͟ published 
in this issue of JAACAP is, in my view as a practicing clinician and researcher, one of the most interesting 
and important papers I have read this year. Individuals with Intellectual Disability (ID) are known to be at 
substantially elevated risk for psychopathology2 so mental health clinicians will be involved in their 
assessment and treatment. ID spans a very broad range of IQ test scores and functioning, so affected 
individuals are not necessarily immediately recognizable.  Previous research of those with ID already 
tells us that Attention Deficit Hyperactivity Disorder (ADHD)  is one of the most commonly co-occurring 
conditions1. Although that is also the case for Autism Spectrum Disorder (ASD), historically comorbidity 
between ID and ADHD has been dealt with very differently. The association between ASD and ID has 
long been accepted3. However clinicians and researchers have been plagued by concerns that ADHD 
features are an epiphenomenon of ID. This has led not only to diagnostic over-shadowing and a failure 
to treat ADHD in those with ID in some instances1 but also to research exclusions. For example, 
historically molecular genetic studies of schizophrenia and autism have not supported excluding 
participants on the basis of lower IQ or ID4. In contrast, although ADHD shows a similar strong 
association with lower IQ as one might expect for a neurodevelopmental disorder, typically those with 
low IQ have been excluded5or separated in analysis6 thereby diminishing the available research evidence 
base for these individuals as well as research applicability to daily practice. The findings from the paper 
by X et al. in this issue challenge this historical trend. 
The authors took advantage of nationwide Swedish registry data on around 2 million people to examine 
diagnoses of ID and ADHD in tens of thousands of relatives who differ in their degree of biological 
relatedness. They included MZ and DZ twin pairs, parent-offspring, sibling half sibling and cousin pairs. 
They observed that ADHD and ID strongly share genetic risks. That is, ADHD rates were observed to be 
higher not only in individuals with ID (probands) but also in their biological relatives; ADHD risk was 
highest in those most closely related to the probands and not explained by probands who had both 
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phenotypes (i.e. ID and ADHD). Interestingly, findings were different for the most severe form of ID 
(profound ID) which did not show familial co-aggregation with ADHD. This finding is in keeping with the 
view that ID mainly lies at one end of a multi-factorial, polygenic continuum of intellectual ability 
whereas profound ID is etiologically distinct and qualitatively different from the rest of the IQ spectrum 
and mild-moderate ID7. This discontinuity appears to apply to the familial co-aggregation with ADHD and 
might be explained by rare causes including genetic syndromes (e.g. de novo/non-inherited mutations) 
and environmental agents (e.g. intra-uterine exposure to infection) contributing to profound ID. The 
authors discuss the strengths and limitations of their study including the reliance on registry data and 
recorded diagnoses. Nevertheless it is of interest and relevance that directly assessed  population-based 
twin studies (e.g. involving interviews and questionnaire measures) also have shown a strong genetic 
correlation between lower  IQ test scores and ADHD8 (as well as with other neurodevelopmental traits 
such as ASD3). The etiologies of ID and ADHD are mainly polygenic (explained by multiple, different gene 
variants) and multi-factorial (non-genetic risks also contribute). The findings in this paper should not 
detract from remembering that ID and ADHD, like most common medical conditions, have complex 
etiologies. The genetic correlation estimates also will include gene-environment correlation and 
interaction effects. 
 
Why is this important?  For clinicians, it is likely that we already appreciate the elevated rates of ADHD 
in those with ID when assessing and planning treatment. This paper serves as a reminder. However, as is 
the case for autism, we might be less surprised now if families report a family history of ID (amongst 
other neurodevelopmental disorders). In the future, this finding could have relevance to genetic 
counsellors. ADHD treatments are effective in those with ID9 so the presence of ID should not deter us 
from treating those affected. However there is a higher risk of side effects so careful monitoring is 
required.  
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For researchers, this paper conveys a very important message. There really are no good scientific (or of 
course ethical) reasons for excluding individuals with ID from our research studies including ones on 
ADHD. ADHD phenotype presentations and outcomes are similar or more severe in those with ID versus 
the rest of the population10 and this paper provides further evidence of a shared genetic etiology 
between ADHD and ID/IQ across most of the IQ spectrum. Indeed, this finding supports the DSM-5 
approach to grouping child neurodevelopmental disorders whereby ADHD, ID, ASD, communication, 
learning and motor disorders are grouped together. The move away from unhelpful exclusion criteria is 
welcome as is the greater use of dimensional approaches. Whilst over-zealous diagnosis and over-
treatment are to be guarded against in those with ID, appropriate, careful assessment and treatment 
are important as is scientific endeavor that includes the full spectrum of intellectual ability.  
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